- $128.21m
- -$54.56m
Brief: Nkarta Q4 Net Income USD -25.935 Million
Nkarta Inc expected to post a loss of 41 cents a share - Earnings Preview
Brief: Nkarta Inc Clinical Data From Ntrust-1 And Ntrust-2 Planned For 2025
U.S. RESEARCH ROUNDUP-Microstrategy, Snowflake, Target
Nkarta Inc reports results for the quarter ended in September 30 - Earnings Summary
Brief: Nkarta Q3 Net Income USD -28.344 Million
Nkarta Inc expected to post a loss of 36 cents a share - Earnings Preview
Brief: Nkarta Q2 Net Income USD -24.993 Million
Nkarta Inc expected to post a loss of 45 cents a share - Earnings Preview
Brief: Nkarta Announces Initiation Of Investigator-Sponsored Clinical Trial Evaluating NKX019 For Systemic Lupus Erythematosus
Brief: Nkarta Initiates Clinical Trial Of Nkx019 In Lupus Nephritis
Brief: Nkarta Adds Experienced Leader In Autoimmune Research And Development, George Vratsanos, M.D., Facr, To Board Of Directors
Nkarta Inc reports results for the quarter ended in January - Earnings Summary
Brief: Nkarta Expects Current Cash, Cash Equivalents Will Be Sufficient To Fund Its Current Operating Plan Into Late 2027
Brief: Nkarta Q1 Net Income USD -29.518 Million
Nkarta Inc expected to post a loss of 56 cents a share - Earnings Preview
U.S. RESEARCH ROUNDUP-Altair Engineering, Applied Therapeutics, Microsoft
Brief: Nkarta Announces Pricing Of $240 Million Underwritten Offering
U.S. STOCKS ON THE MOVE-Reddit, Alphabet, Tesla